Full Press Release Details
Zynex Announces 4th Quarter and Year-End
Revenue Guidance Update
LONE TREE, Colo., Jan. 8, 2018 /PRNewswire/ -- Zynex,
Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices
for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced an update to its previously
announced revenue estimate for the fourth quarter.
Zynex updates its Fourth Quarter Revenue Estimate to between $7.5 and $8.0
million. The previous estimate, established in November 2017 was between $7.0 and $7.5 million. The revenue
in the fourth quarter of 2016 was $2.9 million and the most recent third quarter of 2017 was $6.8 million. The full
year 2017 revenue is now estimated to come in between $22.8 and $23.3 million compared to $13.3 million in
2016. The company expects to file its full year and fourth quarter financials on or before March 31, 2018.
Zynex reports its financial results in accordance with accounting
principles generally accepted in the U.S. (GAAP). In addition, the Company is providing in this news release financial information
in the form of adjusted EBITDA (earnings before interest, taxes, depreciation, amortization and stock compensation). Management
believes these non-GAAP financial measures are useful to investors and lenders in evaluating the overall financial health of the
Company in that they allow for greater transparency of additional financial data routinely used by management to evaluate performance.
Adjusted EBITDA can be useful for investors or lenders as an indicator of earnings available to service debt. Non-GAAP financial
measures should not be considered in isolation from or as an alternative to the financial information prepared in accordance with
Zynex, founded in 1996,
markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's
proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new
blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.
Safe Harbor Statement
statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual
results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results
to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or
augment our liquidity in order to continue our business, the success of our international expansion efforts, our ability to engage
additional sales representatives and their success, the need to obtain FDA clearance and CE marking of new products, the acceptance
of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the
need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or
rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers
to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force,
the uncertain outcome of pending material litigation, our ability to up-list to a larger exchange and other risks described in
our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on
Form 10-K for the year ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's
Contact: Zynex, Inc. (303)
Amato And Partners, LLC
Investor Relations Counsel